KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Net Cash Flow (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Net Cash Flow for 7 consecutive years, with -$11.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 147.66% to -$11.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$186.5 million through Dec 2025, up 16.71% year-over-year, with the annual reading at -$186.5 million for FY2025, 16.71% up from the prior year.
  • Net Cash Flow hit -$11.7 million in Q4 2025 for GoodRx Holdings, down from -$7.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $32.9 million in Q3 2023 to a low of -$147.4 million in Q1 2025.
  • Historically, Net Cash Flow has averaged -$35.5 million across 5 years, with a median of -$8.1 million in 2024.
  • Biggest five-year swings in Net Cash Flow: soared 1976.68% in 2023 and later crashed 3655.01% in 2024.
  • Year by year, Net Cash Flow stood at $29.1 million in 2021, then dropped by 2.43% to $28.4 million in 2022, then plummeted by 532.04% to -$122.6 million in 2023, then skyrocketed by 120.04% to $24.6 million in 2024, then plummeted by 147.66% to -$11.7 million in 2025.
  • Business Quant data shows Net Cash Flow for GDRX at -$11.7 million in Q4 2025, -$7.8 million in Q3 2025, and -$19.7 million in Q2 2025.